share_log

藥明康德:翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

HKEX ·  Sep 12, 2024 04:57

Summary by Moomoo AI

無錫藥明康德新藥開發股份有限公司於2024年9月11日及12日進行了股份回購,分別回購了522,300股及985,200股A股股份。該公司股份在上海證券交易所上市,並根據相關規則進行了此次回購。根據香港聯合交易所有限公司的規定,公司已確認所有交易均獲得董事會授權,並遵守了所有適用的上市規則、法律及其他監管規定。此次股份回購後,公司的已發行股份總數維持在2,524,851,053股,未有變動。
無錫藥明康德新藥開發股份有限公司於2024年9月11日及12日進行了股份回購,分別回購了522,300股及985,200股A股股份。該公司股份在上海證券交易所上市,並根據相關規則進行了此次回購。根據香港聯合交易所有限公司的規定,公司已確認所有交易均獲得董事會授權,並遵守了所有適用的上市規則、法律及其他監管規定。此次股份回購後,公司的已發行股份總數維持在2,524,851,053股,未有變動。
Wuxi Apptec conducted a share repurchase on September 11 and 12, 2024, repurchasing 522,300 shares and 985,200 shares of A-shares, respectively. The company's shares are listed on the Shanghai Stock Exchange, and this repurchase was carried out in accordance with relevant rules. As per the regulations of the Hong Kong Stock Exchange, the company has confirmed that all transactions were authorized by the board of directors and complied with all applicable listing rules, laws, and other regulatory requirements. Following this share repurchase, the total number of issued shares of the company remains at 2,524,851,053 shares, with no changes.
Wuxi Apptec conducted a share repurchase on September 11 and 12, 2024, repurchasing 522,300 shares and 985,200 shares of A-shares, respectively. The company's shares are listed on the Shanghai Stock Exchange, and this repurchase was carried out in accordance with relevant rules. As per the regulations of the Hong Kong Stock Exchange, the company has confirmed that all transactions were authorized by the board of directors and complied with all applicable listing rules, laws, and other regulatory requirements. Following this share repurchase, the total number of issued shares of the company remains at 2,524,851,053 shares, with no changes.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more